Drugs / RO7497372
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06847854 | Dec 2022 → Nov 2026 expected | diabetic macular edema | Genentech, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7497372 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06847854 ↗ |
| Route | Intravitreal | “administered as IVT injection” NCT06847854 ↗ |